LOGO
LOGO

Email This Article

Silexion Completes Toxicology Studies For SIL204; Phase 2/3 Pancreatic Cancer Trial To Begin In Q2
To Email: *
Bcc: Seperate multiple addresses with commas(,)
Your Email: *
Format :

* Denotes Required Fields